Real options analysis on strategic partnerships of biotechnological start-ups

Abstract

Since there is a mismatch between long-term basic research and short-term financial markets, the dependency of biotechnology (biotech) start-ups on strategic partnerships with pharmaceutical companies is expanding more than on venture capital. The research objectives are to examine the difference between license-fee elements, try to determine the innovation valuation in strategic partnerships, and minimise the risk in partnership formation for both sides. A key concept is that a biotech start-up is defined as a portfolio of real options based on an entrepreneur's ideas about investment opportunity. Methodologies used are compound options and stochastic optimisation for innovative but risky projects. In conclusion, this paper tries to address a wider scope with a deeper theoretical grounding, by using the real options perspective for the valuation of innovation partnership, through a biotech license-fee case study for simulation. Furthermore, the real option valuation can be expected to improve open innovation from matchmaking to innovation partnership.